# US 2021/0277091 A1 · Immunoglobulin constant region fc receptor binding agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277091 A1
- Document ID: US20210277091A1
- Status: Published application
- Kind: A1
- Application number: 17/163,618
- Filed: 2021-02-01
- Published: 2021-09-09
- Earliest claimed: 2007-06-01
- Assignees: University of Maryland, Baltimore; Gliknik Inc.
- Applicants: University of Maryland, Baltimore; Gliknik Inc.
- Inventors: Scott E. STROME; Dan H. SCHULZE; David S. BLOCK; Henrik OLSEN
- Web page: https://patentgrep.com/patent/US20210277091A1

## CPC

- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/22: for herpes viruses
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/065: {Purification, fragmentation}
- C07K 16/18: against material from animals or humans
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/32: against translation products of oncogenes
- G01N 33/5047: {Cells of the immune system}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- C07K 2317/35: Valency
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/50: characterized by immunoglobulin fragments
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/528: CH4 domain
- C07K 2317/53: Hinge
- C07K 2317/55: Fab or Fab'
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2318/00: Antibody mimetics or scaffolds
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- G01N 2500/10: involving cells
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A method of treating an autoimmune or inflammatory disease comprising administering to a subject in need thereof a composition comprising a cluster stradomer comprising at least two multimerized cluster stradomer units,
wherein each of said cluster stradomer units comprises at least one multimerizing region selected from an IgG2 hinge or an isoleucine zipper and at least one Fc domain comprising a CH2 domain and a CH3 domain from IgG1 or IgG3 or a combination thereof,
wherein the multimerizing region(s) of the at least two cluster stradomer units multimerize to form the cluster stradomer, and
wherein the cluster stradomer is capable of specifically binding to at least two Fc receptors.

### Claim 22 (depends on 21)

The method of claim 21, wherein the cluster stradomer comprises two multimerized cluster stradomer units.

### Claim 23 (depends on 21)

The method of claim 21, wherein the cluster stradomer comprises at least three multimerized cluster stradomer units.

### Claim 24 (depends on 21)

The method of claim 21, wherein the cluster stradomer comprises at least four multimerized cluster stradomer units.

### Claim 25 (depends on 21)

The method of claim 21, wherein the cluster stradomer comprises at least five multimerized cluster stradomer units.

### Claim 26 (depends on 21)

The method of claim 21, wherein the at least one Fc domain comprises an IgG1 hinge, an IgG1 CH2 domain, and an IgG1 CH3 domain.

### Claim 27 (depends on 21)

The method of claim 21, wherein the at least one Fe domain comprises an IgG3 hinge, an IgG3 CH2 domain, and an IgG3 CH3 domain.

### Claim 28 (depends on 21)

The method of claim 21, wherein at least one of the cluster stradomer units comprises two or more Fc domains.

### Claim 29 (depends on 21)

The method of claim 21, wherein each of the cluster stradomer units is capable of specifically binding to at least one FcR.

### Claim 30 (depends on 29)

The method of claim 29, wherein the at least one FcR is human Fcγ receptor I, human Fcγ receptor II, human Fcγ receptor III, or human Fcγ receptor IV.

### Claim 31 (depends on 30)

The method of claim 30, wherein the human Fcγ receptor III is human Fcγ receptor IIIa.

### Claim 32 (depends on 21)

The method of claim 21, wherein the at least one multimerizing region is an IgG2 hinge.

### Claim 33 (depends on 21)

The method of claim 21, wherein the cluster stradomer is administered intravenously, subcutaneously, orally, intranasally, rectally, intraperitoneally, sublingually, buccally, transdermally, by subdermal implant, or intramuscularly.

### Claim 34 (depends on 21)

The method of claim 21, wherein the subject in need thereof suffers from an autoimmune or inflammatory disease that can be treated by IVIG.

### Claim 35 (depends on 21)

The method of claim 21, wherein the inflammatory disease is idiopathic thrombocytopenic purpura.

### Claim 36 (depends on 21)

The method of claim 21, wherein the autoimmune disease is systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyradiculoneuropathy or type 1 diabetes.

### Claim 37

A method of treating an autoimmune or inflammatory disease comprising administering to a subject in need thereof a composition comprising a cluster stradomer comprising at least two multimerized cluster stradomer units,
wherein each of said cluster stradomer units comprises an IgG2 hinge multimerizing region and an IgG1 Fc domain comprising a CH2 and CH3 domain,
wherein the IgG2 hinge multimerizing region of the at least two cluster stradomer units multimerize to form the cluster stradomer, and
wherein the cluster stradomer is capable of specifically binding to at least two Fcγ receptors.

### Claim 38

A method of treating an autoimmune or inflammatory disease comprising administering to a subject in need thereof a composition comprising a cluster stradomer comprising at least two multimerized cluster stradomer units,
wherein each of said cluster stradomer units comprises an IgG2 hinge multimerizing region and an IgG3 Fc domain comprising a CH2 and CH3 domain,
wherein the IgG2 hinge multimerizing region of each of the at least two cluster stradomer units multimerize to form the cluster stradomer, and
wherein the cluster stradomer is capable of specifically binding to at least two Fcγ receptors.
